Santen Pharmaceutical Co (SNPHY)
Company Info
Highlights
$3.09B
$0.52
16.87
$153.90B
$87.85B
$20.42B
$8.65 - $13.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Santen Pharmaceutical Co, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Santen Pharmaceutical Co had a return of -13.34% year-to-date (YTD) and -10.87% in the last 12 months. Over the past 10 years, Santen Pharmaceutical Co had an annualized return of -2.97%, while the S&P 500 had an annualized return of 11.31%, indicating that Santen Pharmaceutical Co did not perform as well as the benchmark.
SNPHY
-13.34%
-10.78%
-23.54%
-10.87%
-12.79%
-2.97%
^GSPC (Benchmark)
4.46%
2.46%
9.31%
23.49%
13.03%
11.31%
Monthly Returns
The table below presents the monthly returns of SNPHY, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 1.19% | -13.34% | |||||||||||
| 2024 | 0.91% | -1.11% | -0.81% | 1.95% | 3.32% | -0.68% | 15.20% | 5.53% | 2.10% | -6.48% | -10.39% | -4.62% | 2.74% |
| 2023 | -4.10% | -1.69% | 11.61% | -3.07% | 11.46% | -7.66% | 2.37% | 6.94% | -1.30% | -4.71% | 9.90% | 3.14% | 22.51% |
| 2022 | -7.14% | 0.18% | -11.92% | -18.94% | -0.74% | -2.74% | 2.69% | -10.97% | -5.18% | 0.89% | 17.13% | 0.50% | -33.99% |
| 2021 | 3.20% | -18.70% | 1.68% | -7.35% | 3.58% | 3.83% | -2.31% | 11.62% | -6.70% | 0.21% | -6.74% | -7.38% | -25.14% |
| 2020 | -1.76% | -15.33% | 7.98% | 3.65% | 4.46% | 0.14% | -8.79% | 13.45% | 7.82% | -12.31% | -8.88% | -0.91% | -13.99% |
| 2019 | -3.60% | 13.24% | -3.65% | 3.08% | -6.80% | 15.07% | -2.24% | 10.30% | -1.71% | 2.07% | 6.83% | 0.66% | 35.27% |
| 2018 | 4.44% | -2.08% | 5.18% | 0.09% | 3.27% | 0.46% | -4.53% | -7.87% | 4.53% | -6.22% | 15.90% | -16.89% | -7.24% |
| 2017 | 2.25% | 14.52% | 2.54% | -2.97% | -2.13% | -1.60% | 4.51% | 9.96% | 2.53% | 0.90% | -3.37% | 2.18% | 31.68% |
| 2016 | -3.58% | -3.52% | -1.26% | -4.66% | 1.78% | 7.24% | 5.76% | -24.14% | 18.18% | -0.92% | -15.13% | -1.09% | -24.63% |
| 2015 | 16.43% | 7.42% | 11.10% | -10.10% | 5.81% | 2.04% | 3.66% | 6.11% | -12.72% | 1.05% | 17.51% | 3.71% | 59.48% |
| 2014 | -9.11% | 9.60% | -1.82% | 2.13% | 22.17% | 2.07% | 3.70% | -1.24% | -1.21% | 6.53% | -6.09% | -4.13% | 20.88% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of SNPHY is 31, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Santen Pharmaceutical Co (SNPHY) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Santen Pharmaceutical Co provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.00 | $0.27 | $0.26 | $0.24 | $0.23 | $0.23 | $0.24 | $0.44 | $0.64 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 2.20% | 1.63% | 1.25% | 1.62% | 1.48% | 1.98% | 2.65% | 5.97% |
Monthly Dividends
The table displays the monthly dividend distributions for Santen Pharmaceutical Co. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.00 | $0.00 | $0.00 | ||||||||||
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.14 | $0.00 | $0.00 | $0.00 | $0.27 |
| 2020 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.00 | $0.26 |
| 2019 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.00 | $0.24 |
| 2018 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.11 | $0.00 | $0.00 | $0.00 | $0.23 |
| 2017 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.12 | $0.00 | $0.00 | $0.00 | $0.23 |
| 2016 | $0.00 | $0.00 | $0.13 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.11 | $0.00 | $0.00 | $0.00 | $0.24 |
| 2015 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.10 | $0.00 | $0.00 | $0.00 | $0.44 |
| 2014 | $0.34 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.29 | $0.00 | $0.00 | $0.00 | $0.64 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Santen Pharmaceutical Co. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Santen Pharmaceutical Co was 69.09%, occurring on Nov 8, 2022. The portfolio has not yet recovered.
The current Santen Pharmaceutical Co drawdown is 57.84%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -69.09% | Sep 30, 2020 | 532 | Nov 8, 2022 | — | — | — |
| -34.58% | Feb 4, 2016 | 215 | Dec 8, 2016 | 253 | Dec 11, 2017 | 468 |
| -33.75% | Jan 16, 2020 | 41 | Mar 16, 2020 | 128 | Sep 16, 2020 | 169 |
| -27.32% | Jun 18, 2018 | 164 | Feb 11, 2019 | 187 | Nov 6, 2019 | 351 |
| -24.63% | Sep 26, 2011 | 24 | Nov 29, 2011 | 92 | Aug 14, 2012 | 116 |
Volatility
Volatility Chart
The current Santen Pharmaceutical Co volatility is 19.29%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Santen Pharmaceutical Co compared to its peers in the Drug Manufacturers - General industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for SNPHY in comparison to other companies of the Drug Manufacturers - General industry. Currently, SNPHY has a PE value of 16.9. This PE value is considered to be low compared to the rest of the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for SNPHY in comparison to other companies of the Drug Manufacturers - General industry. Currently, SNPHY has a PEG value of 0.0. This PEG value is considered to be low compared to the rest of the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Santen Pharmaceutical Co.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |